Consensus Haemonetics Corporation

Stocks

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 23:00:03 10/07/2026 +03			5-day change	1st Jan Change
76.19 ^USD	+1.59%		+1.49%	-4.94%

06-29	Haemonetics Corporation(NYSE:HAE) added to Russell 2000 Value Benchmark	CI
06-29	Haemonetics Corporation(NYSE:HAE) added to Russell 2000 Value-Defensive Index	CI

Evolution of the Average Target: Haemonetics Corporation

Evolution of the Target Price: Haemonetics Corporation

Changes in Analyst Recommendations: Haemonetics Corporation

564566b6e13554a.LpBqTjux369ZnFs5cXfHuDEwpUl3QOhJKI8Vf0TPFM8.H-lYIwPk7dca0HZ6RBaA-mRz5DM2EpAYQcZhS3CDe45v0gkJD9-s3xitaw~f2cc5214a8410a172e62102f165df627

Analysts' recommendations: Haemonetics Corporation

05-22	Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says	MT
05-22	BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80	MT
05-12	Barrington Cuts Price Target on Haemonetics to $89 From $94, Keeps Outperform Rating	MT
01-12	Barrington Adjusts Price Target on Haemonetics to $93 From $90, Maintains Outperform Rating	MT
12-15	Needham Downgrades Haemonetics to Hold From Buy, Removes $78 Price Target	MT
12-11	Citigroup Downgrades Haemonetics to Neutral From Buy, Adjusts PT to $88 From $77	MT
11-07	Haemonetics Taking Prudent View on Guidance After Plasma Recovery, BofA Says	MT
11-07	BofA Securities Upgrades Haemonetics to Neutral From Underperform, Raises Price Target to $75 From $58	MT
11-07	Needham Raises Price Target on Haemonetics to $78 From $68, Keeps Buy Rating	MT
11/08/25	Haemonetics Shares Fall After Raymond James Downgrade	MT
11/08/25	Raymond James Downgrades Haemonetics to Outperform From Strong Buy	MT
08/08/25	Haemonetics Shares Fall After JPMorgan Downgrade	MT
08/08/25	Needham Cuts Price Target on Haemonetics to $68 From $84, Keeps Buy Rating	MT
08/08/25	JPMorgan Downgrades Haemonetics to Neutral From Overweight, Adjusts Price Target to $62 From $85	MT
09/07/25	Haemonetics Shares Rise After Upgrade From Citigroup	MT
09/07/25	Citigroup Upgrades Haemonetics to Buy From Neutral, Lifts Price Target to $90 From $71	MT
09/07/25	Analyst recommendations: Illumina, Freeport-McMoran, XPO, T-Mobile US…
26/06/25	Baird Initiates Coverage on Haemonetics With Outperform Rating, $87 Price Target	MT
18/03/25	Needham Trims Price Target on Haemonetics to $104 From $108, Keeps Buy Rating	MT
06/12/24	JPMorgan Initiates Haemonetics at Overweight With $116 Price Target	MT
10/09/24	BTIG Initiates Haemonetics at Buy With $112 Price Target	MT
09/08/24	Barrington Research Raises Price Target on Haemonetics to $108 From $107, Maintains Outperform Rating	MT
12/06/24	Haemonetics Shares Rise After Upgrade From Needham	MT
12/06/24	Needham Upgrades Haemonetics to Buy From Hold, Sets Price Target at $112	MT
10/05/24	Barrington Research Raises Price Target on Haemonetics to $107 From $105, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	HAEMONETICS CORPORATION					+13.01%
	ABBOTT LABORATORIES					+23.92%
	MEDTRONIC PLC					+15.66%
	CENCORA, INC.					+16.5%
	HOYA CORPORATION					+21.64%
	BECTON, DICKINSON AND COMPANY					+16.44%
	MEDLINE INC.					+24%
	DEXCOM, INC.					+13.71%
	WEST PHARMACEUTICAL SERVICES, INC.					+3.45%
	STERIS PLC					+18.92%
	Average					+16.72%
	Weighted average by Cap.					+18.88%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

76.19USD

Average target price

86.10USD

Spread / Average Target

+13.01%

High Price Target

104.00USD

Spread / Highest target

+36.50%

Low Price Target

62.00USD

Spread / Lowest Target

-18.62%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
Barrington Research
Needham & Co.
Citigroup
Raymond James
JPMorgan Chase
Baird
BTIG
Morgan Stanley
JMP Securities
Mizuho Securities
CJS Securities